Immunological Efficacy of a Prime-boost Strategy Combining a 7-valent Pneumococcal Conjugate Vaccine (PCV) Followed by a 23-valent Pneumococcal Polysaccharide Vaccine (PPV) Versus PPV Alone in HIV-infected Adults. ANRS 114 PNEUMOVAC.
Sponsor study identifier
interventional
212
1 country
1
Study Start
February 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
January 2006
Actual (reported)Streptococcus pneumoniae is the major cause of bacterial infection in HIV-infected patients. The current pneumococcal vaccine is poorly efficacious in patients with a CD4 cell count lower than 500/mm3. This study will test the efficacy and safety of a new pneumococcal vaccine strategy in patients with a CD4 cell count between 200 and 500/mm3.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2003
Date type not reportedThis date has not been verified as actual or estimated.
September 7, 2005
Actual (reported)September 8, 2005
Actual (reported)January 2006
Actual (reported)Proportion of patients responders to 7 pneumococcal polysaccharides at W8
Persistence of antibody responses at W24 and W96
Clinical tolerance of pneumococcal vaccines at W8
Evolution of the CD4 count and plasma HIV RNA load
Immunological substudy (predictive factors of the antibody responses) at W24
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Service d'Immunologie Clinique
Créteil, 94010, France
Lesprit P, Pedrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, Katlama C, Yeni P, Morineau P, Delfraissy JF, Chene G, Levy Y; ANRS 114-Pneumovac Study Group. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS. 2007 Nov 30;21(18):2425-34. doi: 10.1097/QAD.0b013e3282887e91.
Rabian C, Tschope I, Lesprit P, Katlama C, Molina JM, Meynard JL, Delfraissy JF, Chene G, Levy Y; ANRS 114 Pneumovac Study Group. Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults. Clin Infect Dis. 2010 Apr 15;50(8):1174-83. doi: 10.1086/651418.
Philippe Lesprit, MD
Service d'Immunologie Clinique, Créteil, 94010, France
Geneviève Chêne, MD, PhD
INSERM unité 593
First Submitted
September 7, 2005
First Posted
September 8, 2005
Study Start
February 2003
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
January 2006
Actual (reported)Contact the study team to confirm eligibility.
Last Updated
June 15, 2026
Record last verified: 2008-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: